Although its enzymatic activity remains enigmatic, PNPLA3 I148M represents an important emerging prognostic marker for risk stratification and a potential therapeutic target because of its major implications for the risk of progression toward more advanced fibrosis and HCC in virtually all major hepatic disorders. This evidence concerns the gene PNPLA3 and liver disorder.